Forth Therapeutics launches with Sofinnova backing

Forth Therapeutics, a UK biotechnology company focused on precision treatments for fibrosis, has launched with support from European venture capital firm Sofinnova Partners and Old College Capital, the University of Edinburgh’s investment arm.

The company, based in Edinburgh and Cambridge, draws from work by fibrosis researcher Neil Henderson. It is led by Alex Leech, a biotech entrepreneur and partner at Sofinnova.

Forth will get to work on a portfolio of three drug candidates targeting fibrosis across multiple organ systems, using omics technology and benefitting from access to one of the world’s largest single-cell human liver disease datasets.